Want to join the conversation?
$PFE announced data from an ongoing, investigational Phase 1b study of Inlyta in a treatment-naive patients with advanced renal cell carcinoma (RCC), a common type of kidney cancer. The data from a trial of Inlyta wth pembrolizumab provides additional support for novel immunotherapy combinations in RCC.
$WTW Great marketing execution and overwhelming response to the development strategy is seeing the stock boom. Biggest intraday gain ( 30%) since Nov. 2015. Hats off to Oprah Winfrey !!
$HSY is planning to cut its global workforce by 15%.
$ACN spreading its arms!! Now into pipeline network and emergency management services, thanks to the latest Davies Consulting buy.